Experience of short-term hydroxychloroquine and azithromycin in COVID-19 patients and effect on QTc trend
We have read the paper on concerns in prescribing COVID-19 treatment in this journal with great interest.1 With the scale of transmission and mortality risk, there is an urgent need to identify an effective antiviral. Combinational hydroxychloroquine and azithromycin emerge as potential therapy but yielded mixed results from clinical studies2-5 and raising concerns over cardiovascular safety.6,7 We would like to report risk profile, QTc trend and outcomes of 13 COVID-19 confirmed patients admitted to Taiping Hospital, Perak, Malaysia between 21 March 2020 and 13 April 2020, with mild to moderate diseases who were commenced on hydroxychloroquine with without azithromycin.
Source: Journal of Infection - Category: Infectious Diseases Authors: Hor Chee Peng, Narwani Hussin, Saravanaa Nalliah, Way Ti Ooi, Xing Yi Tang, Sara Zachariah, Gurpreet pal Singh Jugindar Singh, Rosilawati Abdul Rani, Kunaraj Perumal, Cheah Wee Kooi Tags: Letter to the Editor Source Type: research
More News: Azithromycin | Cardiology | Cardiovascular | COVID-19 | Heart | Hospitals | Hydroxychloroquine | Infectious Diseases | Malaysia Health | Zithromax